Victory Capital Management
LUCD icon

Victory Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Victory Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19K Buy
17,747
+7,634
+75% +$8.23K ﹤0.01% 2445
2026
Q1 		$11.6K Sell
10,113
-722
-7% -$919 ﹤0.01% 2392
2025
Q4 		$11.8K Buy
+10,835
New +$12.1K ﹤0.01% 2406

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Victory Capital Management's LUCD Position: Q2 2026 in Review

Victory Capital Management increased its Lucid Diagnostics (LUCD) stake by 75% in Q2 2026, buying an estimated $8.23K and bringing the position to 17,747 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #2445.

Victory Capital Management first reported a position in LUCD in Q4 2025 and has held it in 3 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Victory Capital Management held 17,747 shares of Lucid Diagnostics worth $19K as of Q2 2026.
  • Victory Capital Management bought 7,634 Lucid Diagnostics shares in Q2 2026, an estimated $8.23K.
  • Lucid Diagnostics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2445 holding.
  • Victory Capital Management first reported a position in Lucid Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.